Changing the Paradigm in Oncology Clinical Trials

AI Meets Cancer Patients and Clinical Trials

CEO and Co-Founder, Selin Kurnaz discusses how Massive Bio is changing the paradigm in oncology clinical trials at the Ai4 2nd Annual Artificial Intelligence Healthcare Conference in New York. Some of the other speakers are from top providers, payers, pharma, biotech, medical device, startups, health tech, and many more industries. This conference highlighted the advances being made in terms of applying artificial intelligence to the healthcare industry.

You can learn more about Massive Bio here. 

Media Coverage Press Releases

Comments

  • George ,

    Thank you, I’ve recently been looking for information approximately this subject for a while. However, what in regards to the bottom line? How will artificial intelligence impact cancer treatment?

  • Fiona Evans ,

    George, Thank you for reaching out. Our Artificial Intelligence database will search through over 11,000 clinical trials and match you to the best/most appropriate ones that you appear to be eligible for based off of your medical records. It will allow you the opportunity to choose from immunotherapy, chemotherapy and/or targeted therapy clinical trials that you may not have had to opportunity to be apart of without our Artificial Intelligence database.

  • Leave a Comment

    Your email address will not be published.

    Previous reading
    Cancer Patient Enrollment Improvement Key to Clinerion Partnership
    Next reading
    Top 128 Cancer Startups